I think better efficacy is not on the menu and that they would be happy with improved safety profile without losing Gilenya like efficacy. That goes for all next gen S1PR agonists players.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.